Ramucirumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Biliary Tract Cancer · Phase 2 · investigational in the US

Also approved (3)
CA
  • CYRAMZA® (ramucirumab) is indicated for: • Gastric Cancer – CYRAMZA (ramucirumab) as a single agent or in combination with paclitaxel is indicated for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma, with disease progression on or after prior platinum and fluoropyrimidine chemotherapy.
Product first approved 2015Health Canada
JP
  • Treatment of unresectable advanced or recurrent gastric cancer
Product first approved 2015PMDA
EU
  • Gastric/GEJ adenocarcinoma first; EPAR now also lists metastatic colorectal cancer, NSCLC, hepatocellular carcinoma
Product first approved 2014EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (16)
Advanced Metastatic Colorectal Cancer
NCT03520946 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2019-01-24 – 2024-07-30 · Colorectal Cancer
What this study did
Gastric Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07763171 · Gruppo Oncologico del Nord-Ovest
2026-09-01 – 2031-09 · Gastroesophageal Adenocarcinoma
What this study did
NCT04675983 · Innovent Biologics (Suzhou) Co. Ltd.
2021-03-10 – 2023-02-12 · Gastric Adenocarcinoma
What this study did
NCT02934464 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2016-12 – 2021-12 · Stomach Neoplasms
What this study did
NCT02898077 · Eli Lilly and Company
2017-03-02 – 2021-04-12 · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
What this study did
NCT02314117 · Eli Lilly and Company
2015-01-20 – 2020-08-14 · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2/3 (5)
Gastric Cancer
NCT06203600 · National Cancer Institute (NCI)
2024-06-24 – 2027-10-31 · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05002127 · ALX Oncology Inc.
2022-01-15 – 2026-06-30 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
What this study did
NCT03081143 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2017-05-10 – 2026-05-04 · Advanced Gastric or EGJ Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06616584 · SWOG Cancer Research Network
2025-05-22 – 2028-12-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
Other / comorbidity
NCT02661971 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2016-06 – 2022-06-20 · Stomach Cancer, Gastroesophageal Junction Cancer
What this study did
Phase 2 (81)
Biliary Tract Cancer
Colorectal Cancer
NCT01111604 · Eli Lilly and Company
2010-08 – 2013-12 · Colon Cancer, Rectal Cancer
What this study did
NCT00862784 · Eli Lilly and Company
2009-04 – 2011-08 · Colorectal Carcinoma
What this study did
Gastric Cancer
NCT06962137 · Universitaire Ziekenhuizen KU Leuven
2025-12-11 – 2030-08-30 · Gastric Cancer Adenocarcinoma Metastatic, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07669740 · The First Affiliated Hospital with Nanjing Medical University
2026-07-01 – 2028-12-30 · Gastric Cancer (Diagnosis)
What this study did
NCT04069273 · Harry H Yoon
2020-12-01 – 2027-12-10 · Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
What this study did
NCT06038578 · Toray Industries, Inc
2023-10-04 – 2027-10-31 · Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06251973 · Memorial Sloan Kettering Cancer Center
2024-02-01 – 2027-08-01 · Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Cancer, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Carcinoma, Unresectable Esophageal Cancer, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT02678182 · Royal Marsden NHS Foundation Trust
2015-02 – 2027-06 · Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
What this study did
NCT04660760 · Academic and Community Cancer Research United
2021-06-16 – 2026-11-30 · Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
What this study did
NCT06564298 · The First Affiliated Hospital with Nanjing Medical University
2024-08 – 2026-06 · Stomach Neoplasms
What this study did
NCT04632459 · Samsung Medical Center
2021-06-16 – 2025-01-15 · Gastric Cancer
What this study did
NCT05942573 · Tianjin Medical University Cancer Institute and Hospital
2022-12-24 – 2024-12-31 · Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
What this study did
NCT03760822 · Federation Francophone de Cancerologie Digestive
2018-11-16 – 2024-12 · Stomach Cancer, Stomach Neoplasm, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05071053 · Sanofi
2021-11-16 – 2024-11-05 · Adenocarcinoma Gastric, Gastrooesophageal Cancer
What this study did
NCT03686488 · H. Lee Moffitt Cancer Center and Research Institute
2018-12-20 – 2024-05-31 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
What this study did
NCT05311176 · Imugene Limited
2022-08-17 – 2024-04-04 · Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma, Stomach Cancer, Stomach Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05190445 · Pieris Pharmaceuticals, Inc.
2021-11-01 – 2023-02-01 · HER2-positive Gastric Cancer
What this study did
NCT03766607 · Korean South West Oncology Group
2019-09-30 – 2022-06-30 · Gastric Cancer
What this study did
NCT02726399 · Memorial Sloan Kettering Cancer Center
2016-03-18 – 2019-02-26 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT02514551 · Eli Lilly and Company
2015-10-12 – 2018-12-28 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT01983878 · Eli Lilly and Company
2013-12 – 2016-02 · Gastric Cancer
What this study did
Hepatocellular Carcinoma
NCT06441019 · Fudan University
2024-07-01 – 2026-05-31 · Hepatocellular Carcinoma,Bispecific Antibodies, HAIC, Ramucirumab
What this study did
NCT01246986 · Eli Lilly and Company
2011-03-30 – 2019-12-24 · Carcinoma, Hepatocellular
What this study did
NCT00627042 · Eli Lilly and Company
2008-02 – 2011-05 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04340882 · Emory University
2020-06-05 – 2030-09-30 · Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT07098338 · AstraZeneca
2025-08-07 – 2029-04-06 · Non-Small Cell Lung Cancer
What this study did
NCT05642572 · SWOG Cancer Research Network
2023-05-05 – 2028-06-30 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT06031688 · SWOG Cancer Research Network
2024-08-08 – 2028-05-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT04040361 · National Cancer Center Hospital East
2019-11-30 – 2027-12-31 · Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA
What this study did
NCT06448754 · AstraZeneca
2024-08-27 – 2027-07-30 · Non-small Cell Lung Cancer
What this study did
NCT04332367 · Abramson Cancer Center at Penn Medicine
2020-08-01 – 2027-06-01 · Non-small Cell Lung Cancer
What this study did
NCT03527108 · Fox Chase Cancer Center
2020-10-08 – 2027-04 · Non Small Cell Lung Cancer
What this study did
NCT03909334 · Xiuning Le
2019-07-25 – 2027-01 · Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
What this study did
NCT05007769 · Washington University School of Medicine
2021-10-31 – 2026-04-30 · Non-small Cell Lung Cancer, Non-small Cell Carcinoma, NSCLC, Non Small Cell Lung Cancer
What this study did
NCT04394624 · Sanofi
2020-08-31 – 2024-10-24 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT03689855 · Washington University School of Medicine
2019-06-05 – 2024-04-22 · Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC
What this study did
NCT03971474 · SWOG Cancer Research Network
2019-05-28 – 2024-01-01 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT04120454 · Ohio State University Comprehensive Cancer Center
2020-06-17 – 2023-08-19 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03904108 · ROGER S KERESZTES MD
2019-06-27 – 2020-07-27 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02730247 · Liza Villaruz, MD
2017-07-05 – 2019-09-08 · Non-small Cell Lung Cancer
What this study did
NCT02831491 · Eli Lilly and Company
2016-11 – 2018-01 · Stage IV Non-small Cell Lung Cancer
What this study did
NCT01703091 · Eli Lilly and Company
2012-12 – 2016-07 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT00735696 · Eli Lilly and Company
2009-01 – 2012-01 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05980000 · Washington University School of Medicine
2023-10-27 – 2030-06-30 · Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC
What this study did
NCT07546812 · Gilead Sciences
2026-08-07 – 2030-01 · HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
What this study did
NCT04205968 · SWOG Cancer Research Network
2020-06-01 – 2027-08-01 · Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
What this study did
NCT06043427 · Canadian Cancer Trials Group
2024-04-16 – 2027-07-31 · Gastroesophageal Adenocarcinoma
What this study did
Phase 1/2 (19)
Gastric Cancer
NCT05927857 · National Health Research Institutes, Taiwan
2024-04-01 – 2028-12-31 · Metastatic Gastric Adenocarcinoma, Second Line, Chemotherapy
What this study did
NCT05894824 · Yonsei University
2024-02-05 – 2026-01-01 · Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer
What this study did
NCT03008278 · National Cancer Institute (NCI)
2018-02-06 – 2025-08-13 · Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03739801 · University of Southern California
2020-04-06 – 2023-04-06 · Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04888663 · Yonsei University
2018-02-13 – 2021-09-02 · Recurrent/Metastatic Gastric Cancer
What this study did
NCT02999295 · National Cancer Center, Japan
2017-01 – 2019-08 · Gastric Cancer, Gastroesophageal Junction Region (GEJ) Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06996782 · AstraZeneca
2025-11-24 – 2029-02-23 · Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT06007937 · Memorial Sloan Kettering Cancer Center
2023-08-17 – 2028-08-17 · Non Small Cell Lung Cancer, Metastatic, Recurrent
What this study did
NCT04151563 · Bristol-Myers Squibb
2021-04-15 – 2026-05-13 · Carcinoma, Non-small Cell Lung Cancer
What this study did
NCT02082210 · Eli Lilly and Company
2014-03-07 – 2018-01-24 · Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06445972 · Merck Sharp & Dohme LLC
2024-08-07 – 2030-08-08 · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
What this study did
NCT06771622 · FBD Biologics Limited
2025-03-13 – 2029-01-01 · Solid Cancer
What this study did
NCT03650764 · Washington University School of Medicine
2019-05-29 – 2026-05-11 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT04145349 · Eli Lilly and Company
2020-01-22 – 2026-01-23 · Desmoplastic Small Round Cell Tumor
What this study did
NCT04921904 · Baylor Research Institute
2021-06-11 – 2025-08-14 · Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03995017 · University of Kansas Medical Center
2020-01-09 – 2024-12 · Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma
What this study did
NCT03745430 · Hellenic Cooperative Oncology Group
2019-01-29 – 2023-04-23 · Pancreatic Adenocarcinoma
What this study did
NCT04145700 · Eli Lilly and Company
2020-03-04 – 2023-02-23 · Synovial Sarcoma
What this study did
NCT04604132 · Basilea Pharmaceutica
2020-10-06 – 2022-11-21 · Gastric Adenocarcinoma
What this study did
Phase 1 (34)
Colorectal Cancer
NCT03872947 · Toray Industries, Inc
2019-04-26 – 2026-07-16 · Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
What this study did
NCT03798626 · Novartis Pharmaceuticals
2019-05-22 – 2025-02-05 · Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
What this study did
NCT02745769 · Eli Lilly and Company
2016-10-21 – 2019-01-22 · Advanced Cancer, Colorectal Cancer, Mantle Cell Lymphoma
What this study did
Gastric Cancer
NCT07594548 · Northwestern University
2026-11-10 – 2031-09-09 · Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Carcinoma
What this study did
NCT06675136 · City of Hope Medical Center
2025-10-29 – 2029-01-14 · Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
What this study did
NCT02970539 · Athenex, Inc.
2016-12-08 – 2022-12-31 · Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer
What this study did
Hepatocellular Carcinoma
NCT05856864 · Tianjin Medical University Cancer Institute and Hospital
2024-06-01 – 2025-05-01 · Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
What this study did
NCT02069041 · Eli Lilly and Company
2014-04 – 2016-09 · Carcinoma, Hepatocellular
What this study did
Non-Small Cell Lung Cancer
NCT04999761 · Taiho Pharmaceutical Co., Ltd.
2021-06-01 – 2027-06 · Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer, Head and Neck Cancer, Biliary Tract Cancer
What this study did
NCT02789345 · Eli Lilly and Company
2016-10-24 – 2022-05-09 · Non-small Cell Lung Cancer
What this study did
NCT02443324 · Eli Lilly and Company
2015-07-29 – 2022-04-12 · Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer
What this study did
NCT02572687 · Eli Lilly and Company
2016-02-19 – 2021-01-13 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
What this study did
NCT05800418 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2019-11-04 – 2020-02-18 · Gastric Cancer, Non-small Cell Lung Cancer, Colo-rectal Cancer
What this study did
NCT02079636 · Eli Lilly and Company
2014-03-28 – 2019-08-29 · Carcinoma, Non-small Cell Lung
What this study did
Other / comorbidity
NCT05719558 · Astellas Pharma Global Development, Inc.
2023-03-13 – 2030-05-31 · Advanced Solid Tumors
What this study did
NCT05365581 · Astellas Pharma Global Development, Inc.
2022-06-07 – 2028-05-31 · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
What this study did
NCT03013218 · ALX Oncology Inc.
2017-02-03 – 2025-07-08 · Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma
What this study did
NCT05980416 · Elevation Oncology
2023-08-10 – 2025-06-02 · Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
What this study did
NCT02791334 · Eli Lilly and Company
2016-06-29 – 2024-06-27 · Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
What this study did
NCT04557384 · Eli Lilly and Company
2021-02-23 – 2021-05-25 · Advanced Solid Tumor
What this study did
NCT04495478 · Eli Lilly and Company
2020-07-30 – 2021-05-09 · Healthy
What this study did
NCT03193918 · Arog Pharmaceuticals, Inc.
2017-04-14 – 2020-07-15 · Esophagogastric Adenocarcinoma
What this study did
NCT02597036 · Eli Lilly and Company
2015-11-06 – 2020-05-24 · Solid Tumors
What this study did
NCT02564198 · Eli Lilly and Company
2015-12-11 – 2019-07-16 · Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies
What this study did
NCT01285037 · Eli Lilly and Company
2009-09-09 – 2017-09-11 · Cancer
What this study did
NCT02359058 · Eli Lilly and Company
2015-02 – 2016-11 · Stomach Neoplasms
What this study did
NCT01682135 · Eli Lilly and Company
2012-11 – 2015-03 · Solid Tumor
What this study did
NCT01256567 · Eli Lilly and Company
2010-12 – 2013-02 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT01286818 · Eli Lilly and Company
2011-02 – 2012-03 · Colorectal Carcinoma
What this study did
NCT01253525 · Eli Lilly and Company
2010-11 – 2011-10 · Adenocarcinoma
What this study did
NCT01005355 · Eli Lilly and Company
2009-09 – 2011-02 · Advanced Solid Tumors
What this study did
NCT00793975 · Eli Lilly and Company
2005-01 – 2009-06 · Advanced Solid Tumors
What this study did
NCT00786383 · Eli Lilly and Company
2006-02 – 2009-01 · Cancer
What this study did
Phase 4 (1)
Gastric Cancer
NCT06169410 · Yang Jianjun, PhD
2023-12-30 – 2025-12-31 · Advanced Gastric Cancer
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT04517747 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2020-10-15 – 2023-01-20 · Gastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction
What this study did
Used as active comparator (14)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Gastric Cancer
NCT06123494 · Jiangsu HengRui Medicine Co., Ltd.
2024-01-09 – 2027-06-30 · HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06346392 · AstraZeneca
2024-03-04 – 2026-10-14 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT04704934 · Daiichi Sankyo
2021-05-21 – 2026-08-31 · Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
Non-Small Cell Lung Cancer
Phase 2/3 (2)
Non-Small Cell Lung Cancer
NCT05096663 · SWOG Cancer Research Network
2022-03-15 – 2027-12-01 · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
Phase 2 (5)
Gastric Cancer
NCT03704077 · Bristol-Myers Squibb
2019-10-31 – 2024-09-30 · Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
What this study did
Non-Small Cell Lung Cancer
NCT07603856 · University of Chicago
2026-12-12 – 2030-06-25 · Non-Small Cell Lung Cancer, Metastatic Lung Cancer
What this study did
NCT04310007 · National Cancer Institute (NCI)
2020-07-13 – 2027-03-31 · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
Other / comorbidity
NCT06904300 · Sun Yat-sen University
2025-08-15 – 2028-12-31 · Gastric (Cardia, Body) Cancer
What this study did
NCT04267913 · SWOG Cancer Research Network
2020-09-05 – 2026-10-31 · Lung Squamous Cell Carcinoma, Recurrent Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT03281369 · Hoffmann-La Roche
2017-10-13 – 2025-10-09 · Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT05062980 · Genprex, Inc.
2022-03-30 – 2025-02-03 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT03863587 · Shanghai Henlius Biotech
2019-06-06 – 2019-09-24 · Healthy Male Volunteers
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Other / comorbidity
NCT04499924 · Seagen Inc.
2021-03-22 – 2024-04-17 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Advanced Metastatic Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ramucirumab: this drugApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
BafisontamabPhase 2Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
PelareorepPhase 2Oncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(29 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ramucirumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03909334 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03527108 · CT.gov ↗
What to watch
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06043427 · CT.gov ↗
What to watch
2027 (13)
February 2027 (1)
Phase 2Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2027-02-01 · NCT04205968 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Neoplasms, Child, AdolescentRecruiting
Est. primary completion 2027-05 · NCT05999994 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT04999761 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT07669740 · CT.gov ↗
What to watch
Phase 2Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma …Active not recruiting
Est. primary completion 2027-06-30 · NCT05980000 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT05642572 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-30 · NCT06448754 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-08-01 · NCT06251973 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-08-11 · NCT04069273 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-10-31 · NCT06038578 · CT.gov ↗
What to watch
Phase 2/3Gastric CancerRecruiting
Est. primary completion 2027-10-31 · NCT06203600 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2027-12-31 · NCT05927857 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT06616584 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
May 2028 (3)
Phase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal CancerRecruiting
Est. primary completion 2028-05-09 · NCT06445972 · CT.gov ↗
What to watch
Phase 1Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2028-05-31 · NCT05365581 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-05-31 · NCT06031688 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-08-17 · NCT06007937 · CT.gov ↗
What to watch
2029 (5)
January 2029 (1)
Phase 1Gastric CancerRecruiting
Est. primary completion 2029-01-14 · NCT06675136 · CT.gov ↗
What to watch
February 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-23 · NCT06996782 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-04-06 · NCT07098338 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Gastroesophageal AdenocarcinomaNot yet recruiting
Est. primary completion 2029-09 · NCT07763171 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Gastric CancerRecruiting
Est. primary completion 2029-12-31 · NCT06962137 · CT.gov ↗
What to watch
2030 (3)
January 2030 (1)
Phase 2HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric AdenocarcinomaActive not recruiting
Est. primary completion 2030-01 · NCT07546812 · CT.gov ↗
What to watch
April 2030 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2030-04-30 · NCT05719558 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1Gastric CancerRecruiting
Est. primary completion 2030-09-09 · NCT07594548 · CT.gov ↗
What to watch

See the full readout calendar ↗